title: Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world.
abstract: Treatment studies in haemophilia focus on joint bleeds; however, some 10-25% of bleeds occur in muscles. This review addresses management of muscle haematoma in severe haemophilia, defines gaps in the published evidence, and presents a combined clinician and physiotherapist perspective of treatment modalities. The following grade 2C recommendations were synthesized: (i) Sport and activity should be based on individual factor levels, bleeding history and physical characteristics, (ii) Musculoskeletal review aids the management of children and adults, (iii) 'Time to full recovery' should be realistic and based on known timelines from the healthy population, (iv) Diagnosis should be carried out by both a clinician and physiotherapist, (v) Severe muscle bleeds should be treated similarly to surgical patients: a 50% trough for 10-14 days followed by high-level prophylaxis, (vi) Protection, rest, ice, compression and elevation should be implemented in the acute stage, and (vii) Physiotherapy and rehabilitation should be divided into: control of haemorrhage (phase 1); restoration of Range of Movement (ROM) and strength (phase 2); functional rehabilitation and return to normal living (phase 3). Recommendations specifically for inhibitor patients include: (i) Minor to moderate bleeds should be managed by home-treatment within 1 h of bleed onset using either one injection of rFVIIa 270 μg kg(-1), or two to three injections of rFVIIa 90 μg kg(-1) (2-3 h intervals), or FEIBA 50-100 U kg(-1) (repeated at 12-hourly intervals, if necessary) and (ii) Severe muscle bleeds should be supervised by the treatment centre and include bypassing agents until clinical improvement is observed.
authors.affiliation: Haemostasis Research Unit, Centre for Haemophilia and Thrombosis, Guy's and St Thomas Hospital & NHS Foundation Trust & King's College London School of Medicine, London, UK. benny.sorensen@kcl.ac.uk
authors.forename: B
authors.initials: B
authors.lastname: Sørensen
authors.forename: G M
authors.initials: GM
authors.lastname: Benson
authors.forename: M
authors.initials: M
authors.lastname: Bladen
authors.forename: S
authors.initials: S
authors.lastname: Classey
authors.forename: D M
authors.initials: DM
authors.lastname: Keeling
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: T T
authors.initials: TT
authors.lastname: Yee
authors.forename: M
authors.initials: M
authors.lastname: Makris
mesh_terms: D001265:Athletic Injuries / Q000209:etiology / Q000534:rehabilitation; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D003029:Coagulants / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000534:rehabilitation*; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D002836:Hemophilia B / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D009135:Muscular Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control / Q000534:rehabilitation*; D026741:Physical Therapy Modalities
chemical_list: D001779:Blood Coagulation Factors; D003029:Coagulants